

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1642
)	
LONGENECKER, Michael B.)	Examiner: FETTEROLF, B.
)	
Serial No.: 10/594,992)	Washington, D.C.
)	
Filed: November 16, 2006)	May 14, 2009
)	
For: MUCINOUS GLYCOPROTEIN)	Docket No.: LONGENECKER=7A
(MUC-1) VACCINE)	
)	Confirmation No.: 5786

ELECTION WITH TRAVERSE

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

S i r :

1. In response to the restriction requirement mailed January 27, 2009, applicants elect group I (method of treating NSCLC), with partial traverse.

We accede to the restriction between NSCLC and prostate cancer, however, traversal is necessary because claim 1 is mischaracterized. We note that claim 1 encompasses variants of SID1 and 2, as well as SID1 and 2 per se as stated by the restriction.

We traverse, for example, to preserve our rights to limit the claimed invention of groups 1 and 2 to BLP25 (cp. claims 13, 14, 18, 19), which is not identical to Morse's BLP24.

Moreover, in view of the limitation of claim 1 to treatment of NSCLC stage IIIB locoregional, i.e., no malignant pleural effusion, which is not taught by Morse, we believe that Morse's teaching of BLP24¹ vs. NSCLC is not decisive and in particular does not necessitate limitation to a particular SID.

2. In response to the species restriction set forth on page 11 (and prompted by claim 11), we elect species (c) (nodal

¹ Which is 24 a.a. long, not 25 a.a. like SID1 or 27 a.a. like SID2.

USSN - 10/594,992

stage). The examiner concedes that claims 1 and 7 are generic. Claim 7 requires "step (c) evaluating the treated individual". Claims 8-11 address particular methods of evaluation. We believe that all claims except 8-11 are generic, and that claims 8-11 nonetheless read on the elected species.

The species restriction is traversed on the ground that one or more generic claims (e.g., 1) are allowable.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
G:\ipc\A-C\biom\Longenecker7a\pto electiontraverse.wpd